MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.eplepsyres.2019.02.014

Медицинская библиотека · Epilepsy research · 2019

Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome.

Yoshitomi Shinsaku, Takahashi Yukitoshi, Yamaguchi Tokito, Imai Katsumi, Ishii Atsushi, Hirose Shinichi, Inoue Yushi

СтатьяНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: In the present study, we aimed to investigate the efficacy and tolerability of perampanel in patients with Dravet syndrome.

METHODS

We retrospectively reviewed data regarding seizure frequency and adverse effects in 10 patients (four boys, six girls) with Dravet syndrome following treatment with perampanel. Perampanel treatment was considered effective when seizure frequency had been reduced by more than 50%.

RESULTS

The mean age of patients at perampanel introduction was 11.5 ± 2.2 years. Seizure types were as follows: generalized tonic-clonic seizure (n = 8), unilateral clonic seizure (n = 6), myoclonic seizure (n = 3), atypical absence seizure (n = 3), and focal impaired awareness seizure (n = 1). The average number of concomitant anti-epileptic drugs (AEDs) was 3 ± 0.9. The mean duration of perampanel use was 11.1 ± 3.8 months. Seizure frequency was reduced by more than 50% in five patients (50%). The efficacy of perampanel for each seizure type was as follows: generalized tonic-clonic seizure: 50% (4/8), unilateral clonic seizure: 50% (3/6), myoclonic seizure: 33% (1/3), atypical absence seizure: 33% (1/3), and focal impaired awareness seizure: 100% (1/1). The effects of perampanel in each patient occurred between 3 and 6 months following the initiation of treatment. Seizure reduction was observed beginning at perampanel doses of 0.1 ± 0.07 mg/kg/day. Adverse events were observed in seven of 10 patients. Although somnolence was noted in 50% of patients, most events were mild.

CONCLUSIONS

The results of this retrospective observational study indicate that perampanel treatment may be promising in some patients with Dravet syndrome. Additional studies are necessary to verify the actual efficacy of perampanel for Dravet syndrome.

Для цитирования: Yoshitomi Shinsaku, Takahashi Yukitoshi, Yamaguchi Tokito, Imai Katsumi, Ishii Atsushi, Hirose Shinichi, Inoue Yushi. Efficacy and tolerability of perampanel in pediatric patients with Dravet syndrome.. Epilepsy research. 2019. DOI: 10.1016/j.eplepsyres.2019.02.014.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.